Everything below concerns Phase 3 trial. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
=== Arboretum === Much of the main campus has been designated an arboretum. Plants from around the world are labeled along a self-guided plant walk. The Krutch Cactus Garden includes the tallest Boojum tree in the state of Arizona. Two herbaria on the university campus are referred to as "ARIZ" in the Index Herbarium. The campus also boasts hundreds of olive trees many of which were planted by Prof. Robert H. Forbes. Many of these trees are over a hundred years old.
=== International expansion === By the 1950s, supermarkets had become part of the everyday lives of American consumers, but were still extremely rare outside of the United States. Most persons outside the United States had never seen a supermarket or even heard of the term. That began to change after 1956, when the U.S. Department of Agriculture presented an "American Way exhibit" at the International Food Congress in Rome, Italy. The exhibit included "the first fully stocked supermarket outside of the United States". The exhibit was a rather "modest staging" with only about 2,500 items, not a truly comprehensive duplicate of a typical full-size U.S. supermarket, and yet it was much larger than anything the world had ever seen. Just like the American consumers who had entered the first supermarkets two decades earlier, conference attendees, local Italian visitors, and the international news media were all astonished, bewildered, and stunned by the "mountains of food". In 1957, the U.S. Department of Commerce and the National Association of Food Chains orchestrated an even grander presentation, Supermarket USA, at the Zagreb International Trade Fair in what was then part of Yugoslavia. Supermarket USA featured 4,000 consumer items in a 10,000 square-foot (929 m²) exhibit, "the first fully operational American-style supermarket in a communist country".
Sake kasu (酒粕) or sake lees are the pressed lees left from the production of sake (Japanese rice wine). It is a white paste used in cooking. Its taste is fruity and similar to sake. A by-product of Japanese sake production, it typically contains 8% alcohol, has high nutritional value, and might have health benefits. Sake kasu is used as a marinade for Japanese dishes based on fish, vegetables, and meat, and contributes an umami flavor to the dish. Sake kasu is also found in cosmetics and skincare products. Sake kasu is considered a part of the Japanese "no waste" culture since the waste of the sake production is used in various ways. Mirin, a type of sweet Japanese sake, can also produce kasu called mirin kasu. Similar to sake kasu, mirin kasu can also be used as a healthy food ingredient.
9e Compagnie de Commandement et de Transmissions (9e CCT) - Command and Signals Company in Poitiers with VAB Régiment d'Infanterie-Chars de Marine (RICM) - Armoured Marine Infantry Regiment (light cavalry) in Poitiers with AMX 10 RC and ERC 90 1er Régiment d'Infanterie de Marine (1er RIMa) - Armoured Marine Infantry Regiment (light cavalry) in Angoulême with AMX 10 RC and ERC 90 2e Régiment d'Infanterie de Marine (2e RIMa) - Marine Infantry Regiment in Le Mans with VBCI 3e Régiment d'Infanterie de Marine (3e RIMa) - Marine Infantry Regiment in Vannes with VAB 126e Régiment d'Infanterie (126e RI) - Infantry Regiment in Brive-la-Gaillarde with VAB (will be the first unit to receive the new VBMR Griffon in 2018) 11e Régiment d'Artillerie de Marine (11e RAMa) - Marine Artillery Regiment in Saint-Aubin-du-Cormier with TRF1 howitzers, CAESAR self-propelled howitzers and RTF1 mortars 6e Régiment du Génie (6e RG) - Engineer Regiment in Angers
Sources: en.wikipedia.org
==== Surfactants ==== The purpose of surfactants is to mobilize various components of NAPLs by lowering their viscosity and interfacial tension. Solubilizing agents increase the solubility of NAPLs and transfer it to the aqueous phase, allowing it to then be extracted and treated. Mobilizing agents target the residually saturated component of NAPL, allowing it to be displaced by continuous flooding. While surfactants are highly effective, resulting in recovery of 94% of the original DNAPL in case studies, they are also expensive and cost-prohibitive, also potentially adversely affecting the pH of the subsurface environment.
Typically, the complete breakdown of one molecule of glucose by aerobic respiration (i.e. involving glycolysis, the citric-acid cycle and oxidative phosphorylation, the last providing the most energy) is usually about 30–32 molecules of ATP. Oxidation of one gram of carbohydrate yields approximately 4 kcal of energy.
European Union law is a system of supranational laws operating within the 27 member states of the European Union (EU). Originally referred to as Community law, it has grown over time since the 1952 founding of the European Coal and Steel Community, to promote peace, social justice, a social market economy with full employment, and environmental protection. The Treaties of the European Union agreed to by member states form its constitutional structure. EU law is interpreted by, and EU case law is created by, the judicial branch, known collectively as the Court of Justice of the European Union. Legal Acts of the EU are created by a variety of EU legislative procedures involving the popularly elected European Parliament, the Council of the European Union (which represents member governments), the European Commission (a cabinet which is elected jointly by the Council and Parliament) and sometimes the European Council (composed of heads of state). Only the Commission has the right to propose legislation. Legal acts include regulations, which are automatically enforceable in all member states; directives, which typically become effective by transposition into national law; decisions on specific economic matters such as mergers or prices which are binding on the parties concerned, and non-binding recommendations and opinions. Treaties, regulations, and decisions have direct effect – they become binding without further action, and can be relied upon in lawsuits. EU laws, especially Directives, also have an indirect effect, constraining judicial interpretation of national laws.
Female spotted hyenas exposed to larger doses of androgen have significantly damaged ovaries, making it difficult to conceive. After giving birth, the pseudo-penis is stretched and loses much of its original aspects; it becomes a slack-walled and reduced prepuce with an enlarged orifice with split lips. Approximately 15% of the females die during their first time giving birth, and over 60% of their species' firstborn young die. A 2006 Baskin et al. study concluded, "The basic anatomical structures of the corporeal bodies in both sexes of humans and spotted hyenas were similar. As in humans, the dorsal nerve distribution was unique in being devoid of nerves at the 12 o'clock position in the penis and clitoris of the spotted hyena" and that "[d]orsal nerves of the penis/clitoris in humans and male spotted hyenas tracked along both sides of the corporeal body to the corpus spongiosum at the 5 and 7 o'clock positions. The dorsal nerves penetrated the corporeal body and distally the glans in the hyena", and in female hyenas, "the dorsal nerves fanned out laterally on the clitoral body. Glans morphology was different in appearance in both sexes, being wide and blunt in the female and tapered in the male".
Typical antipsychotics: e.g. haloperidol, chlorpromazine. Anti-dopaminergic antiemetics: e.g. droperidol Withdrawal of dopaminergic agents: e.g. levodopa, amantadine It has been purported that there is a genetic risk factor for NMS. In one study, identical twins presented with NMS, and a mother and two of her daughters have presented with NMS in another case. Demographically, it appears that males, especially those under forty, are at greatest risk for developing NMS, although it is unclear if the increased incidence is a result of greater antipsychotic use in men under forty. It has also been suggested that postpartum women may be at a greater risk for NMS. Antipsychotic use in those with Lewy body dementia is a risk factor for NMS. These people are extremely sensitive to antipsychotics. As a result, antipsychotics should be used cautiously in all cases of dementia.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.